tbuckley/cabot-search huggingface dataset:
Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial
Authors: G. Middleton, K. Brock, Y. Summers, J. Connibear, R. Shah, C. Ottensmeier, P. Shaw, S. Ming-Lee, S. Popat, C. Barrie, G. Barone, R. Mant, J.S. Savage, L. Billingham
Journal: Annals of Oncology (2018)
P2.06-09 MiST3: A Phase II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in pts with Malignant Mesothelioma
Authors: M. Krebs, L. Carter, S. Villa, A. King, C. Massey, J. Lorens, E. Darlington, D. Fennell
Journal: Journal of Thoracic Oncology (2018)
Myelin Oligodendrocyte Glycoprotein Antibody–Associated Demyelination Comorbid With Leber Hereditary Optic Neuropathy
Authors: Frank Bittner, Julie Falardeau, Rebecca I. Spain
Journal: JAMA Neurology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
SP0083 Gaps in patient treatment – what patient organisations can do?
Authors: K. Koutsogianni
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Access to healthcare is a basic human right and one of the fundamental principles of European health systems, together with safety, quality, and equity. Unfortunately due to economic crisis and the cuts in healthcare budgets in many countries, inequalities in healthcare have been made worse. Furthermore the healthcare systems are facing increasing demands due to demographic change and the fact that the number of patients with chronic diseases is growing. <h3>Objectives</h3> To identify the inequalities in healthcare system and the degree to which the standards of care are affected. To outline patients organisations challenges in such a demanding environment and their efforts to overcome the gaps in patients’ healthcare. <h3>Methods</h3> Describe the gaps in patients’ access to health care and the degree of their satisfaction from the offered health care services as reflected by the relative EPF survey conducted in 2016 among patients in European countries. In these challenging conditions, patient organisations should help to fill the gaps and suggest specific solutions by raising awareness about the problems of the patients and the consequences of inadequate healthcare. At the same time they should develop collaborations with the scientific and academic community as well as with other patients’ organisations. <h3>Conclusion</h3> Patients with chronic and long term conditions have valuable experience as a result of their interaction with the healthcare system and can identify important gaps and propose solutions in order to improve access to healthcare. <h3>Disclosure of Interest</h3> None declared
Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial
Authors: Francesco D'Aiuto, Nikolaos Gkranias, Devina Bhowruth, Tauseef Khan, Marco Orlandi, Jean Suvan, Stefano Masi, Georgios Tsakos, Steve Hurel, Aroon D Hingorani, Nikos Donos, John E Deanfield, Alastair Lomax, Attila Horvath, Riccardo Zambon, Shiefung Tay, Nikos Tatarakis, Dave Spratt, Isabel Kingston, Mohamed Parkar, Ulpee Darbar, Kalpesh Patel, Elaine Giedrys-Leeper, Zoe Harrington, Kevin Baynes, Francis Hughes, David Gable, Pratik Patel, Ankeet Haria, Michael Lessani, Donna Moskal-Fitzpatrick, Maria Chiara Curra', Banbai Hirani, Kasia Niziolek, Tiffany Mellor
Journal: The Lancet Diabetes & Endocrinology (2018)
Acute upper gastrointestinal bleeding
Authors: Emma Sverdén, Sheraz R Markar, Lars Agreus, Jesper Lagergren
Journal: BMJ (2018)

### What you need to know

Bleeding from the upper gastrointestinal tract (oesophagus, stomach, and duodenum) occurs in approximately 100 per 100 000 people annually.12 It is a medical emergency associated with substantial mortality. A UK audit in 2007 found an overall mortality of 10%.3 This practice pointer provides a guide to the initial management of upper gastrointestinal bleeding and subsequent management of bleeding that results from peptic ulceration, the most common cause (box 1).6

Box 1 
### Causes of upper gastrointestinal bleeding45RETURN TO TEXT

### Assessment and resuscitation

Patients may present with melaena, vomiting fresh blood, or with “coffee ground” vomiting (vomit can take on the appearance of coffee grounds when blood reacts with hydrochloric acid in the stomach). Abdominal pain may also be present. Fresh per rectal bleeding (haematochezia) can occur in major brisk bleeding.7

Assess the patient’s haemodynamic status. Look for visible signs of bleeding. Begin resuscitation in parallel with further clinical assessment. An approach to the initial management of patients with upper gastrointestinal bleeding is shown in the infographic. Early assessment by the intensive care team is recommended in the unstable patient, or where there is airway compromise (such as from haematemesis) or reduced level of consciousness.2 Obtain a medical history alongside a physical examination. Monitor physiological observations including heart rate, blood pressure, respiratory rate, oxygen saturation, and …
P1.12-02 Phase II Study of Amrubicin Monotherapy in Elderly or Poor-Risk Patients with Extensive Disease of Small Cell Lung Cancer
Authors: S. Igawa, T. Fukui, M. Shirasawa, T. Ozawa, H. Sone, S. Kusuhara, N. Nishinarita, Y. Hiyoshi, M. Kubota, H. Mitsufuji, J. Sasaki, M. Katagiri, K. Naoki
Journal: Journal of Thoracic Oncology (2018)
P2.04-20 Immunologic Characterization of Fibrinous Pericarditis as an Immune Checkpoint Blockade Toxicity in NSCLC
Authors: M. Altan, M. Toki, D. Carvajal-Hausdorf, S. Gettinger, R. Herbst, D. Rimm
Journal: Journal of Thoracic Oncology (2018)
Clinical experience with 100 consecutive patients treated with Lu-177-labeled PSMA-I&T radioligand therapy for metastatic castration-resistant prostate cancer: Final analysis
Authors: R.L. Tauber, K. Knorr, S. Schwaiger, M. Retz, T. Maurer, C. D'Alessandria, H.-J. Wester, J. Gschwend, W. Weber, M. Schwaiger, M.M. Heck, M. Eiber
Journal: Annals of Oncology (2018)
P1.13-36 Randomized Phase 2 Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
Authors: L. Sequist, J. Gray, W. Harb, R. Doebele, M. Modiano, D. Jackman, M. Baggstrom, A. Atmaca, E. Felip, M. Provencio, M. Cobo Dols, B. Adiwijaya, G. Kuesters, W. Kamoun, K. Andreas, J. Pipas, S. Santillana, B.C. Cho, K. Park, F. Shepherd
Journal: Journal of Thoracic Oncology (2018)
P1.01-42 Real-World Evaluation of Tolerability in Older Adult Patients (≥75 years old) with EGFR-mutated NSCLC
Authors: S. Jiang, M. Hurry, K. Hueniken, C. Labbe, M.C. Brown, L. Eng, H. Naik, M. Liang, D. Patel, P. Bradbury, N. Leighl, F. Shepherd, W. Xu, G. Liu, R. Walton, G. O'Kane
Journal: Journal of Thoracic Oncology (2018)
Vitamin D<sub>3</sub> Supplementation and Bone Health
Authors: Fuxingzi Li, Xiao Lin, Ling-Qing Yuan
Journal: JAMA Pediatrics (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Tumor growth rate and lenvatinib efficacy in radioiodine-refractory differentiated thyroid cancer
Authors: S. Leboulleux, E.K. Lee, L. Bastholt, M. Tahara, L.J. Wirth, S.I. Sherman, B.G. Robinson, A. Teng, P. Joshi, S. Misir, C.E. Dutcus, R.M. Tuttle, M.J. Schlumberger
Journal: Annals of Oncology (2018)
P2.09-17 A Call to Action: Rapid Collection of Post-Mortem Lung Cancer Tissue in the Community to Enable Lung Cancer Research
Authors: T. Boyle, G. Quinn, M. Schabath, T. Munoz-Antonia, L. Duarte, C. Pratt, D.T. Chen, L.S. Hair, S. Antonia, A. Chiappori, B. Creelan, J. Gray, C. Williams, E. Haura
Journal: Journal of Thoracic Oncology (2018)
Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Abdenour Nabid, Nathalie Carrier, André-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432–31
Authors: Abdenour Nabid, Luis Souhami
Journal: European Urology (2018)
Combined tumor-based BRCA/TP53 mutation testing in ovarian cancer
Authors: B. Edith, A. Leary, P. Pautier, E. Santana, L. Lacroix, O. Cabaret, M. Guillaud-Bataille, J. Michels, A. Auguste, C. Genestie, E. Rouleau
Journal: Annals of Oncology (2018)
P1.03-02 Analysis of SMAD4 Aberrations in Chinese Patients with Non-Small-Cell Lung Cancer
Authors: J. Huang, C. Xu, W. Wang, Q. Zhang, Y. Zhou, W. Zhuang, Y. Zhu, Z. Huang, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2018)
P1.04-11 Exploring the Germ-Line Contribution to Exceptional Response to PD-1/PD-L1 Inhibition in Patients with NSCLC by Whole Genome Sequencing
Authors: M. Barnet, K. Jackson, B. Gao, A. Nagrial, M. Boyer, W. Cooper, R. Hui, A. Linton, M. Tattersall, A. Russell, G. Gibson, J. Cebon, G. Long, A. Menzies, R. Scolyer, P. Lacaze, R. Brink, T. Peters, M. Cowley, V. Gayevskiy, D. Thomas, M. Pinese, P. Blinman, S. Kao, C. Goodnow
Journal: Journal of Thoracic Oncology (2018)
Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC): Initial report of a phase I study, MK3475-223
Authors: A. Ben Nun, N. Golan, E. Ofek, D. Urban, I. Kamer, D. Simansky, A. Onn, A. Ackerstein, S.P. Raskin, T. Shulimzon, N. Zeitlin, I. Redinsky, S. Halperin, M. Jurkowicz, J. Bar
Journal: Annals of Oncology (2018)
P1.01-34 Docetaxel Plus Ramucirumab with Prophylactic PEG-G-CSF Support for Chemo-NaïVe Elderly NSCLC Patients: A Phase II Study (WJOG9416L)
Authors: A. Hata, N. Katakami, M. Shimokawa, S. Sugawara, K. Nishino, S. Hara, H. Nakagawa, M. Mineshita, M. Tachihara, K. Azuma, O. Hataji, H. Tanaka, T. Takahashi, T. Hida, A. Bessho, E. Tabata, H. Watanabe, N. Nogami, T. Yokoyama, H. Hayashi, H. Akamatsu, I. Okamoto, T. Mitsudomi, N. Yamamoto, K. Nakagawa
Journal: Journal of Thoracic Oncology (2018)
P2.09-07 Does Metastatic Site Matter for PD-L1 Testing in Stage IV NSCLC?
Authors: H. Wang, J. Agulnik, G. Kasymjanova, P. Fiset, S. Camilleri-Broët, M. Redpath, D. Small, V. Cohen, A. Spatz
Journal: Journal of Thoracic Oncology (2018)
Open-label multicenter randomized phase II study of docetaxel plus bevacizumab or pemetrexed plus bevacizumab for elderly (≥75 years old) patients (pts) with previously untreated advanced non-squamous non-small cell lung cancer (NSCLC): TORG1323
Authors: T. Honda, T. Kouzuki, Y. Tsunezuka, N. Seki, T. Shibayama, T. Okimoto, H. Taniguchi, Y. Takeda, N. Hata, K. Sugimoto, N. Takahashi, K. Sakai, T. Nishimura, S. Ikeda, S. Watanabe, K. Mori, T. Shinkai
Journal: Annals of Oncology (2018)
Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
Authors: J.F. Blanc, T. Meyer, A.-L. Cheng, A.B. El-Khoueiry, I. Cicin, Y. Chen, L. Bolondi, V. Dadduzio, A. Baron, Z.-Z. Lin, J. Adriani, R.K. Kelly, G.K. Abou-Alfa
Journal: Annals of Oncology (2018)
Abstract 12511: Exercise Stress Test and Myocardial Perfusion Imaging Have Limited Diagnostic Reliability in Detecting Coronary Abnormalities in Children After Arterial Switch Operation for Transposition of the Great Arteries
Authors: Takeshi Tsuda, Abdul M Bhat, Jeanne M Baffa, Wolfgang Radtke, Bradley Robinson
Journal: Circulation (2015)

Background: Exercise stress test (EST) and myocardial perfusion imaging (MPI) are common non-invasive modalities to screen for occult myocardial ischemia, but their sensitivity and specificity in children are unknown. Hypothesis: EST and MPI have limited sensitivity and specificity in detecting occult myocardial ischemia in children. Patients and Methods: We retrospectively reviewed EST, MPI, and coronary angiogram in asymptomatic patients after arterial switch operation (ASO) for d-transposition of the great arteries (TGA) and examined the sensitivity and specificity of EST/MPI in detecting coronary abnormalities. Positive ECG findings for exercise-induced ischemia included ST-T depression &gt; 2mm and exercise-induced ventricular ectopies. Positive MPI is defined as a perfusion defect. Data are shown as mean ± SD. Results: Thirty asymptomatic patients (20 male/10 female; 23 with intact ventricular septum and 7 with ventricular septal defect; ages 12.5 ± 4.4 years) had EST and 26 had simultaneous MPI. Respiratory quotient was 1.11 ± 0.07 and maximum oxygen consumption was 80.7 ± 15.0% predicted, suggesting mildly diminished aerobic fitness level. There was no exercise-induced arrhythmia. Twenty two patients had coronary angiogram (Table 1). Four patients with positive EST and/or MPI were confirmed to have coronary abnormalities by coronary angiogram, whereas 4 patients revealed variable degree of coronary obstruction despite negative EST/MPI including 1 patient who later developed life-threatening ventricular fibrillation. Three patients with positive EST or MPI showed no coronary abnormalities. Conclusions: A combination of EST and MPI has low sensitivity (50%; 4/8) and moderate specificity (79%; 11/14) in detecting coronary abnormalities after ASO. Thus, we recommend performing coronary angiography or equivalent coronary investigation in addition to EST/MPI in children after ASO to detect coronary abnormalities and myocardial ischemia.
Analytical validation of OncoMasTR, a multigene test for predicting risk of distant recurrence in hormone receptor-positive early stage breast cancer
Authors: T. Loughman, A. Chan-Ju Wang, P. Dynoodt, B. Fender, C. Lopez Ruiz, S. Barron, S. Stapleton, D. O’Leary, A. Fabre, C. Quinn, B. Nodin, K. Jirstrom, A. Bracken, W.M. Gallagher
Journal: Annals of Oncology (2018)
Cabazitaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) clinical trials compared to usual care in CAPRI: An observational study in the Netherlands
Authors: H.M. Westgeest, M. Kuppen, A.J.M. van den Eertwegh, J. Van Moorselaar, N. Mehra, I. van Oort, A.C.M. van den Bergh, J.L. Coenen, K.K.H. Aben, R. Somford, R. de Wit, A. Bergman, J. Lavalaye, C.A. Uyl-de Groot, W.R. Gerritsen
Journal: Annals of Oncology (2018)
P1.04-32 Phase I/II Study of the A2AR Antagonist NIR178 (PBF-509), an Oral Immunotherapy, in Patients (pts) with Advanced NSCLC
Authors: A. Chiappori, C. Williams, B. Creelan, T. Tanvetyanon, J. Gray, E. Haura, D.T. Chen, R. Thapa, A. Beg, T. Boyle, M. Sangani, E. Morris, A. Tao, F. Hurtado, L. Manenti, J. Castro, S. Antonia
Journal: Journal of Thoracic Oncology (2018)
The impact of digestion is essential to the understanding of milk as a drug delivery system for poorly water soluble drugs
Authors: Ben J. Boyd, Malinda Salim, Andrew J. Clulow, Gisela Ramirez, Anna C. Pham, Adrian Hawley
Journal: Journal of Controlled Release (2018)

Milk has previously been considered as a potential lipid-based drug delivery system for poorly water soluble drugs but it has never gained significant attention. This is in part because relying on solubility in lipid-based formulations (in this case milk) does not provide a complete picture of the behavior of such systems upon digestion. Herein, we demonstrate using time resolved X-ray scattering that the digestion of milk is actually crucial to the solubilisation of a poorly water-soluble drug, halofantrine. Halofantrine was chosen because its behaviour in lipid-based formulations has been widely investigated and because of its close structural relationship to lumefantrine, an antimalarial drug of current interest for the treatment of paediatric malaria. The transformation of the drug from a crystalline solid form in suspension in milk, to a solubilised form as a direct consequence of lipolysis highlights that consideration of digestion of the milk lipids as a critical process that influences drug solubilisation and availability for absorption is vital.
P1.01-67 Clinical Relevance of ALK/ROS1 Resistance Mutations and Other Acquired Mutations Detected by Liquid Biopsy in Advanced NSCLC Patients
Authors: L. Mezquita, A. Swalduz, C. Jovelet, S. Ortiz-Cuaran, D. Planchard, V. Avrillon, G. Recondo, S. Marteau, V. Plagnol, K. Howarth, C. Morris, E. Green, L. Lacroix, L. Odier, E. Rouleau, P. Fournel, C. Caramella, C. Tissot, J. Adam, M. Pérol, L. Friboulet, P. Saintigny, B. Besse
Journal: Journal of Thoracic Oncology (2018)
P2.13-04 Outcomes of ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Crizotinib: A Multicenter Cohort Retrospective Study.
Authors: P. Xing, Q. Wang, D. Ma, X. Hao, M. Wang, Y. Wang, L. Shan, T. Xin, L. Liang, H. Liang, Y. Du, Z. Zhang, J. Li
Journal: Journal of Thoracic Oncology (2018)
CD49b defines functionally mature Treg cells that survey skin and vascular tissues
Authors: Xiying Fan, Bruno Moltedo, Alejandra Mendoza, Alexey N. Davydov, Mehlika B. Faire, Linas Mazutis, Roshan Sharma, Dana Pe’er, Dmitriy M. Chudakov, Alexander Y. Rudensky
Journal: The Journal of Experimental Medicine (2018)

Regulatory T (Treg) cells prevent autoimmunity by limiting immune responses and inflammation in the secondary lymphoid organs and nonlymphoid tissues. While unique subsets of Treg cells have been described in some nonlymphoid tissues, their relationship to Treg cells in secondary lymphoid organs and circulation remains unclear. Furthermore, it is possible that Treg cells from similar tissue types share largely similar properties. We have identified a short-lived effector Treg cell subset that expresses the α2 integrin, CD49b, and exhibits a unique tissue distribution, being abundant in peripheral blood, vasculature, skin, and skin-draining lymph nodes, but uncommon in the intestines and in viscera-draining lymph nodes. CD49b+ Treg cells, which display superior functionality revealed by in vitro and in vivo assays, appear to develop after multiple rounds of cell division and TCR-dependent activation. Accordingly, single-cell RNA-seq analysis placed these cells at the apex of the Treg developmental trajectory. These results shed light on the identity and development of a functionally potent subset of mature effector Treg cells that recirculate through and survey peripheral tissues.
A randomized phase Ib/II study of the selective small molecule Axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Authors: O. Straume, J.B. Lorens, G. Gausdal, B.T. Gjertsen, C. Schuster
Journal: Annals of Oncology (2019)
P1.14-21 Circulating Biomarkers in Thymic Epithelial Tumors
Authors: D. Valdivia, D. Cheufou, B. Fels, S. Puhlvers, G. Weinreich, D. Theegarten, T. Plönes, K. Mardanzai, M. Zaatar, B. Hegedus, G. Stamatis, C. Aigner
Journal: Journal of Thoracic Oncology (2018)
Use of the Cardiovascular Health Index to assess cardiovascular health in China: an integral innovative approach
Authors: Maigeng Zhou, Jing Liu, Yingying Jiang, Fan Mao, Yichong Li, Yan Zhang, Yong Jiang, Shiwei Liu, Jianqun Dong, Dong Zhao, Linhong Wang, Yong Huo, Junbo Ge
Journal: The Lancet (2018)
Long-Acting HIV Drugs for Treatment and Prevention
Authors: Roy M. Gulick, Charles Flexner
Journal: Annual Review of Medicine (2018)

Antiretroviral drugs have revolutionized the treatment and prevention of HIV infection; however, adherence is critical for sustained efficacy. Current HIV treatment consists of three-drug regimens, and current HIV pre-exposure prophylaxis (PrEP) consists of a two-drug regimen; both generally require adherence to once-daily dosing. Long-acting formulations are useful in the treatment and prevention of other conditions (e.g., contraceptives, antipsychotics) and help promote adherence. Newer long-acting formulations of approved and investigational antiretroviral drugs in existing and newer mechanistic classes are under study for HIV treatment and prevention, including some phase III trials. Although long-acting antiretroviral drugs hold promise, some clinical challenges exist, including managing side effects, drug-drug interactions, pregnancy, and long-lasting drug concentrations that could lead to the development of drug resistance. This review aims to summarize currently available information on long-acting antiretroviral drugs for HIV treatment and prevention.
Phase I/II study of valproic acid (VPA) and short-course radiotherapy (SCRT) plus capecitabine (CAP) as preoperative treatment in low-moderate risk rectal cancer (V-shoRT-R3)
Authors: A. Budillon, P. Delrio, B. Pecori, F. Tatangelo, E. Di Gennaro, C. Romano, V. D'Angelo, P. Marone, C. Granata, E. Cavalacanti, A. De Stefano, U. Pace, F. Bianco, A. Petrillo, S. Lastoria, G. Botti, P. Muto, F. Perrone, M.C. Piccirillo, A. Avallone
Journal: Annals of Oncology (2018)
An exploratory study of intraperitoneal paclitaxel combined with mFOLFOX6 for peritoneal disseminated gastric cancer patients with inadequate oral intake
Authors: S. Kadowaki, H. Ishigami, K. Muro, S. Yoshida, Y. Hirono, T. Tomita, H. Yabusaki, T. Kusumoto, M. Ota, Y. Kodera, Y. Tsuji, A. Hidemura, O. Hachiya, K. Oba, J. Kitayama
Journal: Annals of Oncology (2018)
P1.08 Identification of Three Genomic Regions with Multiple Consecutive Prostate Cancer Susceptibility Loci Through a Genome-Wide Association Study in ARAB Population
Authors: L. Chouchane, S. Shan, K. al-Rumaihi, I. al-Bozom, S. al-Said, D. Rabah, K. Farhat, D. Kizhakayil, I. Aigha
Journal: Annals of Oncology (2012)
P2.16-19 Feasibility and Outcomes of Radiofrequency Ablation as Salvage Modality After Hypofractionated Radiation/SBRT for Early NSCLC
Authors: R. Harjani Hinduja, J. Seely, A. Gupta, V. Nair, G. Cook, R. Macrae
Journal: Journal of Thoracic Oncology (2018)
Phase Ib/II study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression
Authors: J. Rosenberg, A. Necchi, R.F. Sweis, K. Nakajima, C. Lu, H. Nogai
Journal: Annals of Oncology (2018)